* . *
  • About
  • Advertise
  • Privacy & Policy
  • Contact
Sunday, August 24, 2025
Earth-News
  • Home
  • Business
  • Entertainment
    Drake Appears in Teaser for Bobbi Althoff’s New Podcast ‘Not This Again’ – yahoo.com

    Drake Drops a Surprise Cameo in Bobbi Althoff’s Thrilling New Podcast Teaser ‘Not This Again

    From polka to Poison, Corn Palace adjusts entertainment offerings with the times – Mitchell Republic

    From polka to Poison, Corn Palace adjusts entertainment offerings with the times – Mitchell Republic

    How to watch ‘F1: The Movie’ on Prime Video – About Amazon

    Experience the Thrill: How to Stream ‘F1: The Movie’ on Prime Video

    FOX One is now available on Prime Video: Here’s everything to know – About Amazon

    FOX One is now available on Prime Video: Here’s everything to know – About Amazon

    What Are Our Predictions for Taylor Swift’s ‘Life of a Showgirl’ Based on What She’s Told Us So Far? – yahoo.com

    Uncover the Hidden Surprises in Taylor Swift’s ‘Life of a Showgirl’ – Can You Decode Her Clues?

    Bama Dining Serving Up New Food, Entertainment – UA News Center

    Bama Dining Launches Thrilling New Food and Entertainment Experiences

  • General
  • Health
  • News

    Cracking the Code: Why China’s Economic Challenges Aren’t Shaking Markets, Unlike America’s” – Bloomberg

    Trump’s Narrow Window to Spread the Truth About Harris

    Trump’s Narrow Window to Spread the Truth About Harris

    Israel-Gaza war live updates: Hamas leader Ismail Haniyeh assassinated in Iran, group says

    Israel-Gaza war live updates: Hamas leader Ismail Haniyeh assassinated in Iran, group says

    PAP Boss to Niger Delta Youths, Stay Away from the Protest

    PAP Boss to Niger Delta Youths, Stay Away from the Protest

    Court Restricts Protests In Lagos To Freedom, Peace Park

    Court Restricts Protests In Lagos To Freedom, Peace Park

    Fans React to Jazz Jennings’ Inspiring Weight Loss Journey

    Fans React to Jazz Jennings’ Inspiring Weight Loss Journey

    Trending Tags

    • Trump Inauguration
    • United Stated
    • White House
    • Market Stories
    • Election Results
  • Science
  • Sports
  • Technology
    UNLV Responds to Workforce Need with Microcredential in Nuclear Technology – University of Nevada, Las Vegas | UNLV

    UNLV Unveils Cutting-Edge Microcredential Program to Fuel Growth in Nuclear Technology

    Why Technology Will Never Take Over Completely – Patheos

    Why Technology Will Never Completely Control Our Lives

    Alcorn State awarded grant to boost STEM with VR technology – WJTV

    Alcorn State Secures Grant to Transform STEM Education Through Cutting-Edge VR Technology

    Hyundai: The Only Way To Beat China Is To Embrace Technology – InsideEVs

    Hyundai’s Bold Strategy to Outpace China with Cutting-Edge Technology

    Teaching older adults how to use technology – WWNY

    Empowering Older Adults to Master Technology with Confidence

    Denver man receives pacemaker using new technology – CBS News

    Denver Man’s Life Transformed by Revolutionary Pacemaker Technology

    Trending Tags

    • Nintendo Switch
    • CES 2017
    • Playstation 4 Pro
    • Mark Zuckerberg
No Result
View All Result
  • Home
  • Business
  • Entertainment
    Drake Appears in Teaser for Bobbi Althoff’s New Podcast ‘Not This Again’ – yahoo.com

    Drake Drops a Surprise Cameo in Bobbi Althoff’s Thrilling New Podcast Teaser ‘Not This Again

    From polka to Poison, Corn Palace adjusts entertainment offerings with the times – Mitchell Republic

    From polka to Poison, Corn Palace adjusts entertainment offerings with the times – Mitchell Republic

    How to watch ‘F1: The Movie’ on Prime Video – About Amazon

    Experience the Thrill: How to Stream ‘F1: The Movie’ on Prime Video

    FOX One is now available on Prime Video: Here’s everything to know – About Amazon

    FOX One is now available on Prime Video: Here’s everything to know – About Amazon

    What Are Our Predictions for Taylor Swift’s ‘Life of a Showgirl’ Based on What She’s Told Us So Far? – yahoo.com

    Uncover the Hidden Surprises in Taylor Swift’s ‘Life of a Showgirl’ – Can You Decode Her Clues?

    Bama Dining Serving Up New Food, Entertainment – UA News Center

    Bama Dining Launches Thrilling New Food and Entertainment Experiences

  • General
  • Health
  • News

    Cracking the Code: Why China’s Economic Challenges Aren’t Shaking Markets, Unlike America’s” – Bloomberg

    Trump’s Narrow Window to Spread the Truth About Harris

    Trump’s Narrow Window to Spread the Truth About Harris

    Israel-Gaza war live updates: Hamas leader Ismail Haniyeh assassinated in Iran, group says

    Israel-Gaza war live updates: Hamas leader Ismail Haniyeh assassinated in Iran, group says

    PAP Boss to Niger Delta Youths, Stay Away from the Protest

    PAP Boss to Niger Delta Youths, Stay Away from the Protest

    Court Restricts Protests In Lagos To Freedom, Peace Park

    Court Restricts Protests In Lagos To Freedom, Peace Park

    Fans React to Jazz Jennings’ Inspiring Weight Loss Journey

    Fans React to Jazz Jennings’ Inspiring Weight Loss Journey

    Trending Tags

    • Trump Inauguration
    • United Stated
    • White House
    • Market Stories
    • Election Results
  • Science
  • Sports
  • Technology
    UNLV Responds to Workforce Need with Microcredential in Nuclear Technology – University of Nevada, Las Vegas | UNLV

    UNLV Unveils Cutting-Edge Microcredential Program to Fuel Growth in Nuclear Technology

    Why Technology Will Never Take Over Completely – Patheos

    Why Technology Will Never Completely Control Our Lives

    Alcorn State awarded grant to boost STEM with VR technology – WJTV

    Alcorn State Secures Grant to Transform STEM Education Through Cutting-Edge VR Technology

    Hyundai: The Only Way To Beat China Is To Embrace Technology – InsideEVs

    Hyundai’s Bold Strategy to Outpace China with Cutting-Edge Technology

    Teaching older adults how to use technology – WWNY

    Empowering Older Adults to Master Technology with Confidence

    Denver man receives pacemaker using new technology – CBS News

    Denver Man’s Life Transformed by Revolutionary Pacemaker Technology

    Trending Tags

    • Nintendo Switch
    • CES 2017
    • Playstation 4 Pro
    • Mark Zuckerberg
No Result
View All Result
Earth-News
No Result
View All Result
Home Health

A Win and A Loss for Adjuvant ICIs in Clear Cell Renal Cell Carcinoma

January 29, 2024
in Health
A Win and A Loss for Adjuvant ICIs in Clear Cell Renal Cell Carcinoma
Share on FacebookShare on Twitter

SAN FRANCISCO — The use of adjuvant pembrolizumab (Keytruda) boosted overall survival (OS) in post-surgical patients with clear cell renal cell carcinoma (RCC) at risk for recurrence, according to KEYNOTE-564 findings.

Patients treated with the immune checkpoint inhibitor (ICI) had a 38% reduced risk of death compared to patients on placebo, reported Tony Choueiri, MD, of the Dana-Farber Cancer Institute in Boston.

“Between 1973 and now, there have been 17 randomized controlled trials with over 12,000 patients with kidney cancer who were enrolled on adjuvant therapies on RCC, with zero survival improvement,” Choueiri said. “This is the first study to show a statistically significant and clinically meaningful survival improvement with any adjuvant therapy in kidney cancer,” he said at the Genitourinary Cancers Symposium (GuCS).

However, results from a second trial presented at GuCS offered less positive results: In part B of CheckMate 914, nivolumab (Opdivo) monotherapy as an adjuvant treatment failed to improve disease-free survival (DFS) versus placebo in patients with localized RCC at high risk of relapse after nephrectomy.

KEYNOTE-564

At a median follow up of 57.2 months, median OS was not reached in either trial arm, and resulted in an HR 0.62 (95% CI 0.44-0.87, P=0.002) in favor of pembrolizumab.

OS at 1 year was 98.6% with pembrolizumab versus 98.0% with placebo, while 4-year OS rates were 91.2% and 86.0%, respectively.

DFS results were similar to those demonstrated in an earlier interim analysis in which KEYNOTE-564 met its primary endpoint of DFS. In the latest analysis, adjuvant pembrolizumab reduced the risk of disease recurrence or death by 28% (HR 0.72, 95% CI, 0.59-0.87) compared to placebo.

The updated results “further support adjuvant pembrolizumab as a standard of care after surgery in this disease setting,” Choueiri said.

The study enrolled 994 patients (median age 60; about 70% male) with high-risk clear cell RCC who were randomized to the two arms.

Most patients (over 90%) were categorized as M0, with about 85% M0 intermediate-high risk.

Treatment-related adverse events (TRAEs) occurred in 79.1% of patients in the pembrolizumab arm and 53.0% of patients in the placebo arm. Grade 3-4 TRAEs occurred in 18.6% and 1.2% of patients in the two arms, respectively.

TRAEs resulting in discontinuation of any treatment occurred in 18.2% and 0.8% of patients in the two arms.

No treatment-related deaths occurred.

CheckMate 914

Part A of the CheckMate-914 trial previously failed to show a DFS benefit with nivolumab plus ipilimumab (Yervoy) compared with placebo in patients with localized RCC at high risk of post-nephrectomy relapse.

Part B was designed to complement part A by also assessing adjuvant nivolumab monotherapy. It showed that at a median follow-up of 27 months and a median treatment duration of 5.1 months, median DFS was not reached in either the nivolumab or placebo arm (HR 0.87, 95% CI, 0.62-1.21, P=.396), reported Robert Motzer, MD, of Memorial Sloan Kettering Cancer Center in New York City.

At 18 months, DFS rates were 78.4% in the nivolumab arm and 75.4% in the placebo arm.

Thus, “the primary endpoint of DFS for nivolumab monotherapy was not met,” Motzer said.

Motzer added that because the primary endpoint of DFS was not reached, no formal OS analysis will be performed.

Part B included 825 patients — 411 assigned to the nivolumab arm, 208 to placebo, and 206 to nivolumab plus ipilimumab. These patients had a median age of 59, 93% had undergone radical nephrectomy, about 80% had pT3 tumors, while 7-8% had sarcomatoid features, and about 10% had PD-L1>1%.

Among select subgroups there was a trend favoring nivolumab in patients with sarcomatoid features, PD-L1 expression>1%, and those with a lower limit of normal hemoglobin at baseline.

Motzer also reported that DFS outcomes for nivolumab plus ipilimumab were similar in both parts A and B.

Why Only Pembrolizumab?

The results from CheckMate 914 are in line with similar immunotherapy trials that failed to show a DFS benefit as an adjuvant treatment in RCC, leading to the question of why pembrolizumab worked and other agents didn’t.

GuCS discussant Pedro C. Barata, MD, of the University Hospitals Seidman Cancer Center in Cleveland, said the answer to that question “is likely multifactorial.”

“I think factors like histology, different drugs, duration of treatment, patient characteristics like high risk, sarcomatoid features, safety profile, probably all played a role,” he said.

Barata noted that in looking at the DFS curve for KEYNOTE-564 “it’s important to remember that half of post-nephrectomy patients with high-risk features end up being cured and do not require adjuvant therapy.”

However, he added, when one weighs the risks and benefits of adjuvant therapy, “I think the scale tilts towards favoring adjuvant pembrolizumab; as we found out those patients live longer.”

Looking ahead, Barata said, more focus should be placed on how to better identify patients for adjuvant pembrolizumab; treat patients who progress on pembrolizumab; and clarify the role of that drug and other ICIs beyond clear cell RCC.

Disclosures

KEYNOTE 564 was funded by Merck Sharp & Dohme.

CheckMate 914 was funded by Bristol Myers Squibb (BMS). Some co-authors are company employees.

Choueiri and Motzer disclosed multiple relationships with industry.

Barata disclosed relationships with AstraZeneca, Aveo, Bayer, BMS, Caris Life Science, Eisai, EMD Serono, Exelixis, Merck, and Pfizer; institutional relationships with Dendreon, AstraZeneca, Bayer, Caris Life Sciences, Merck, Pfizer/Astellas; and institutional research funding from Aveo, Blue Earth Diagnostics, Exelixis, Merck, and Pfizer.

Primary Source

Genitourinary Cancers Symposium

Source Reference: Motzer R, et al “Adjuvant nivolumab monotherapy vs placebo for localized renal cell carcinoma at high risk of relapse after nephrectomy: results from part B of the randomized, phase 3 CheckMate 914 trial” GuCS 2024; Abstract LBA358.

Secondary Source

Genitourinary Cancers Symposium

Source Reference: Choueiri T, et al “Overall survival results from the phase 3 KEYNOTE-564 study of adjuvant pembrolizumab versus placebo for the treatment of clear cell renal cell carcinoma” GuCS 2024; Abstract LBA359.

>>> Read full article>>>
Copyright for syndicated content belongs to the linked Source : MedPageToday – https://www.medpagetoday.com/meetingcoverage/mgucs/108459

Tags: AdjuvantClearhealth
Previous Post

X hiring content moderators for a new ‘Trust and Safety’ center in Austin

Next Post

Switching Twice With Infliximab Biosimilars Not Linked With IBD Flare Risk

Third annual event highlights cultural, ecological importance of Tawas Lake – Iosco County News Herald

Explore the Vibrant Culture and Stunning Ecology of Tawas Lake at This Year’s Exciting Third Annual Event!

August 24, 2025
UNT Ph.D. Grad Gives $2M to Launch Data Science Innovation Lab – Dallas Innovates

UNT Ph.D. Grad Gives $2M to Launch Data Science Innovation Lab – Dallas Innovates

August 24, 2025
Center to advance hunting and conservation looks to tradition, science – NBC Montana

Center Pioneers New Era in Hunting and Conservation by Merging Tradition with Science

August 24, 2025
‘Hidden gem’ – the lifestyle village beating the property slump – Stuff

‘Hidden gem’ – the lifestyle village beating the property slump – Stuff

August 24, 2025
UNLV Responds to Workforce Need with Microcredential in Nuclear Technology – University of Nevada, Las Vegas | UNLV

UNLV Unveils Cutting-Edge Microcredential Program to Fuel Growth in Nuclear Technology

August 24, 2025
Women’s football moves mountains in Pakistan – EL PAÍS English

Women’s football moves mountains in Pakistan – EL PAÍS English

August 24, 2025
Lifeguard, 82, Sets Impressive Guinness World Record After More Than 60 Years Lifeguarding – People.com

82-Year-Old Lifeguard Breaks Guinness World Record After Over 60 Years on Duty

August 24, 2025
Powell’s Rate Cut Signal Reflects Economy’s Delicate Position – Hindustan Times

Powell’s Rate Cut Signal Reflects Economy’s Delicate Position – Hindustan Times

August 24, 2025
Drake Appears in Teaser for Bobbi Althoff’s New Podcast ‘Not This Again’ – yahoo.com

Drake Drops a Surprise Cameo in Bobbi Althoff’s Thrilling New Podcast Teaser ‘Not This Again

August 24, 2025
Hamilton County school board rejects mental health center contract – Chattanooga Times Free Press

Hamilton County School Board Rejects Contract for New Mental Health Center

August 24, 2025

Categories

Archives

August 2025
MTWTFSS
 123
45678910
11121314151617
18192021222324
25262728293031
« Jul    
Earth-News.info

The Earth News is an independent English-language daily published Website from all around the World News

Browse by Category

  • Business (20,132)
  • Ecology (787)
  • Economy (807)
  • Entertainment (21,686)
  • General (16,641)
  • Health (9,847)
  • Lifestyle (820)
  • News (22,149)
  • People (809)
  • Politics (816)
  • Science (16,019)
  • Sports (21,306)
  • Technology (15,788)
  • World (788)

Recent News

Third annual event highlights cultural, ecological importance of Tawas Lake – Iosco County News Herald

Explore the Vibrant Culture and Stunning Ecology of Tawas Lake at This Year’s Exciting Third Annual Event!

August 24, 2025
UNT Ph.D. Grad Gives $2M to Launch Data Science Innovation Lab – Dallas Innovates

UNT Ph.D. Grad Gives $2M to Launch Data Science Innovation Lab – Dallas Innovates

August 24, 2025
  • About
  • Advertise
  • Privacy & Policy
  • Contact

© 2023 earth-news.info

No Result
View All Result

© 2023 earth-news.info

No Result
View All Result

© 2023 earth-news.info

Go to mobile version